Goldenrod Therapeutics raises $6.5M
Goldenrod Therapeutics announced a Seed round of $6.5M on 4 June 2026. The company operates in HealthTech and is based in United States. It was founded by Dev Chatterjee, CEO.
Founder
Dev Chatterjee
CEO, Goldenrod Therapeutics
Outreach angles
- -Dev Chatterjee leads Goldenrod Therapeutics with a background at Fannin Innovation Studio, a Houston biotech commercialization group.
- -He was educated at the National University of Singapore and now runs a precision-therapeutics company.
- -The $6.5M seed led by Ataxia Ventures advances the lead 11h program for brain inflammation, with the molecule designed by University of Nebraska Medical Center researchers.
Signals
SeedHealthcareDeep TechRegulated IndustryB2B
Round details
Company: Goldenrod Therapeutics
Domain: goldenrodtx.com
Amount: $6.5M
Stage: Seed
Industry: HealthTech
Country: United States
Announced: 4 June 2026
Other HealthTech raises
Recently funded in United States